Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania

Tropical Medicine and International Health

Volumn 4, Issue 5, 1999, Pages 368-376

  Acosta, C J ^a,b   Galindo, C M ^a,b   Schellenberg, D ^a,b   Aponte, J J ^a   Kahigwa, E ^c   Urassa, H ^b   Armstrong Schellenberg, J R M ^b,d   Masanja, H ^b   Hayes, R ^e   Kitua, A Y ^b   Lwilla, F ^f   Mshinda, H ^b   Menendez, C ^a   Tanner, M ^d   Alonso, P L ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c S Francis Designated Dist Hospital   (Tanzania)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f London Sch of Hyg and Trop Med ^*

Author keywords

EPI; Infants; Malaria vaccine; Plasmodium falciparum; SPf 66

Indexed keywords

BCG VACCINE; CHLOROQUINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MALARIA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE;

CHILD HEALTH; DISEASE CONTROL; MALARIA; VACCINATION;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; PLASMODIUM FALCIPARUM; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; TANZANIA; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PROGRAM EVALUATION; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TANZANIA; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

TANZANIA;

EID: 0032978898     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.1999.00406.x     Document Type: Article

References (17)

1. Alonso PL, Smith T, Armstrong Schellenberg JRM et al. (1994) Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344, 1175-1181.
2. Alonso PL, Smith TA, Armstrong-Schellenberg JRM et al. (1996) Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. Journal of Infectious Diseases 174, 367-372.
3. Beck HP, Felger I, Huber W et al. (1997) Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. Journal of Infectious Diseases 175, 921-926.
4. Clayton D (1998) Poisson regression with a random effect. Stata Technical Bulletin 46, 30-33.
5. Galazka A (1990) Simultaneous administration of vaccines. In I° Fòrum internacional sobre associaçao de vacinas. Fundaçao Oswaldo Cruz, Rio de Janeiro, Fiocruz, pp. 24-27.
6. Graves P (1997) Human malaria vaccines: In Infectious Diseases Module of the Cochrane Database Systematic Reviews. Updated 3 June 1997 (eds P Garner, H Gelband, P Olliaro & R Salinas) Available in the Cochrane Library (database on disk and CDROM). The Cochrane Collaboration; Issue 1 (4). Update Software, Oxford.
7. Hatz C, Abdulla S, Mull R et al. (1998) Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Tropical Medicine and International Health 3, 498-504.
8. Kitua AY, Smith T, Alonso PL et al. (1996) Plasmodium falciparum malaria in the first year of life in an area of intense and perennial transmission. Tropical Medicine and International Health 1, 475-484.
9. Lindsey JC (1995) Modelling Frequency and Count Data. Clarendon Press, Oxford.
10. Menendez C, Kahigwa E, Hirt R et al. (1997) Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350, 844-850.
11. Moreno A & Patarroyo ME (1989) Development of an asexual blood stage malaria vaccine. Blood 74, 537-546.
12. Schellenberg D, Acosta CJ, Galindo CM et al. (1999) Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI. Tropical Medicine and International Health 4, 377-382.
13. Smith T, Charlwood JD, Kihonda J et al. (1993) Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Acta Tropical 54, 55-72.
14. Stata Corp. (1997) Stata Statistical Software: Release 5.0. Stata Corporation, College Station, TX.
15. Temple K, Greenwood B, Inskip H, Hall A, Koskela M & Leinonen M (1991) Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Paediatrics Infections Disease Journal 10, 386-390.
16. Teuscher T, Armstrong Schellenberg JRM, Bastos dAI et al. (1994) SPf66, a chemically synthesised subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12, 328-336.
17. World Bank (1993) World Development Report: Investing in Health. Oxford University Press, Oxford.